FATE - Fate Therapeutics Inc. (FATE) CEO Scott Wolchko on Q1 2022 Results - Earnings Call Transcript

Fate Therapeutics, Inc. (FATE) Q1 2022 Earnings Conference Call May 4, 2022 17:00 ET Company Participants Bob Valamehr - Chief Research & Development Officer Scott Wolchko - Founder, President & Chief Executive Officer Ed Dulac - Chief Financial Officer Wayne Chu - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Yigal Nochomovitz - Citigroup Daina Graybosch - SVB Securities Nick Abbott - Wells Fargo Kelsey Goodwin - Guggenheim Mara Goldstein - Mizuho Robyn Karnauskas - Truist Securities Presentation Operator Welcome to the Fate Therapeutics First Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode. This call is being webcasted live on Investors Section of Fate’s website at fatetherapeutics.com. After the speakers presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, today’s call is being recorded. I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics.

For further details see:

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q1 2022 Results - Earnings Call Transcript